<DOC>
	<DOCNO>NCT00831103</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics dosage EPB-348 best balance safety efficacy among adult immunocompetent patient acute episode herpes zoster .</brief_summary>
	<brief_title>A Phase 2b Trial EPB-348 Treatment Herpes Zoster</brief_title>
	<detailed_description>In cell infect varicella-zoster virus , evidence suggest EPB-348 could offer clinically important advantage treatment acute herpes zoster currently available therapy due rapid absorption conversion active moiety well longer intra-cellular half-life infected cell . Clinically , characteristic could translate once-daily dose versus thrice-daily dose see current therapy , lead high rate compliance quality-of-life , especially among elderly patient . The objective EPB348-0201 determine pharmacokinetics dosage EPB-348 best balance safety efficacy among adult immunocompetent patient acute episode herpes zoster . This multi-center study randomly assign patient either EPB-348 1000 mg daily EPB-348 2000 mg daily valacyclovir 1000 mg three time daily .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Male female adult least 18 year age Patients sign symptom consistent acute herpes zoster disease , namely , dermatomal vesicular rash may precede pain parasthesias day vesicular eruption Herpes Zoster associate rash present â‰¤ 72 hour Patients deem immunocompetent base history physical exam Females pregnant nursing History clinical manifestation significant metabolic , hematological , pulmonary , ischemic , unstable heart disease , gastrointestinal , neurological , psychiatric , renal , urological , endocrine , opthalmologic , immune mediate disease include HIV HBsAg positivity Chronic genital herpes Patients receive cytotoxic immunosuppressive drug therapy within 3 month prior study participation Previous vaccination Herpes Zoster Patients &gt; 50 % vesicle crust screen Patients receive topical systemic antiviral medication immunomodulatory agent herpes zoster viral infection capsaicin within 4 week study participation Patients history congenital , acquire , corticosteroid induce immunodeficiency , include malignancy , significantly impaired renal function ( creatinine clearance &lt; 50 cc/min ) , impaired hepatic function ( ALT AST level &gt; 3 time upper limit normal ) QTc &gt; 500msec Patients history intolerance hypersensitivity acyclovir , penciclovir , valacyclovir , famciclovir Patients gastrointestinal dysfunction might interfere drug absorption Patients , consider investigator , reason , unsuitable candidate receiving study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>EPB348</keyword>
	<keyword>Valomaciclovir Stearate</keyword>
	<keyword>Valacyclovir</keyword>
	<keyword>Herpes Zoster</keyword>
	<keyword>Shingles</keyword>
</DOC>